Lung Cancer

Better Care for Minorities, Improved Telehealth: Next Steps in Lung Cancer

February 08, 2021

“We should never be complacent; we should never be skeptical,” said Lilenbaum. “We need to continue to pursue new treatments, and if nothing else, the past 2 decades are a testament to how we can actually make a difference in the natural history of the disease by appropriate interventions.”

Pembrolizumab-Ipilimumab Combo Boosts Toxicity, Not Survival in NSCLC

February 07, 2021

Pembrolizumab (Keytruda) combined with ipilimumab (Yervoy) did not improve survival and had higher rates of toxicity compared with pembrolizumab monotherapy as a first-line treatment for patients with metastatic non–small cell lung cancer (NSCLC) who had a PD-L1 tumor proportion score (TPS) of 50% or greater, and did not harbor EGFR or ALK aberrations.

Adjuvant Osimertinib Helps Maintain Health-Related Quality of Life in NSCLC

February 06, 2021

Health-related quality of life (HRQoL) was maintained for patients with EGFR-positive non–small cell lung cancer (NSCLC) who received treatment with adjuvant osimertinib (Tagrisso) versus placebo, with no clinically meaningful differences noted between study arms, according to an analysis on patient-reported outcomes (PROs) from the phase 3 ADAURA trial.

Patients Need Better Treatment Education, Study Finds

January 31, 2021

Although survivors and patients with lung cancer felt that they were involved in the treatment decision-making process, nearly half of them reported that they knew what their treatment options were before making a decision, according to results from a study presented at the 2020 World Conference on Lung Cancer Singapore.